Jerini's board recommends acceptance of Shire's offer
This article was originally published in Scrip
Executive Summary
Jerini's management and supervisory boards have recommended that the company's shareholders acceptShire's takeover offer of €6.25 per share. Shire, which already owns 80% of Jerini's shares, made the offer in July and has already subscribed to more than five million of the company's shares at a total issue price of around €21 million.
You may also be interested in...
Shire’s Sales, R&D Heads Shed Light On The Post-Baxalta Road Ahead
Shire’s Perry Sternberg and Phil Vickers are optimistic about recent launches and products in late stages of development in key rare disease and specialty therapeutic areas, many of which come from Baxalta and other high-profile acquisitions.
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.